Biodexa Pharmaceuticals (BDRX) Operating Margin (2015 - 2020)
Biodexa Pharmaceuticals' (BDRX) quarterly Operating Margin came in at 13714.29% in Q4 2020, down 1121030.0% year-over-year from N/an in Q1 2020, and down 25.59% quarter-over-quarter from 10919.64% in Q3 2020.
Analysis
Biodexa Pharmaceuticals (BDRX) Operating Margin (2015 - 2020) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Operating Margin across 6 years of filings, most recently posting 13714.29% for Q4 2020.
- In Q4 2020, Operating Margin fell 1121030.0% year-over-year to 13714.29%; the TTM figure through Dec 2020 stood at 1385.74% (down 112933.0% YoY), while the FY2023 annual figure was 2103.41%, down 82559.0% from the prior year.
- Operating Margin came in at 13714.29% for Q4 2020 at Biodexa Pharmaceuticals, down from 10919.64% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 100.67% in Q4 2017 to a low of 13714.29% in Q4 2020.
- Average Operating Margin over 5 years is 4628.93%, with a median of 1404.17% recorded in 2019.
- Year-over-year, Operating Margin surged 21112 bps in 2016 and tumbled 1121030 bps in 2020.
- Over 5 years, Operating Margin stood at 230.68% in 2016, then soared by 56 bps to 100.67% in 2017, then tumbled by 202 bps to 304.35% in 2018, then plunged by 723 bps to 2503.98% in 2019, then slumped by 448 bps to 13714.29% in 2020.
- Per Business Quant data, the three most recent Operating Margin figures were 13714.29% in Q4 2020, 10919.64% in Q3 2020, and 2503.98% in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.97 Bn | 177.80 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.56 Bn | 124.70 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.34 Bn | 74.34 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.73 Bn | 55.54 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 52.08 Bn | 46.95 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.90 Bn | 30.59 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.68 Bn | 29.68 Bn | 1.16 Mn | -25,380.93% |
| 10 | Biodexa Pharmaceuticals | 49.28 Mn | 37.93 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -13,714.29% |
| Sep 10, 2020 | -10,919.64% |
| Dec 31, 2019 | -2,503.98% |
| Dec 31, 2018 | -304.35% |
| Dec 31, 2017 | -100.67% |
| Dec 31, 2016 | -230.68% |
| Dec 31, 2015 | -441.80% |